Moderna and OpenAI Collaborate To Advance mRNA Medicine
Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patientsModerna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT …
Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients
Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise
CAMBRIDGE, MA AND SAN FRANCISCO, CA / ACCESSWIRE / April 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) and OpenAI today announced their ongoing collaboration to co-innovate with a shared vision of AI's transformative potential in the future of business and healthcare. Moderna is a digital-first company that has leveraged the power of machine learning since its beginnings. This strong data foundation, along with its robust culture of learning, positions the Company to responsibly and seamlessly integrate generative AI into its operations and capitalize on next-generation AI innovation.
The organizations began their collaboration in early 2023 with the launch of Moderna's own instance of ChatGPT, called mChat, which was internally built on top of OpenAI's API. With more than 80% internal adoption since its debut, this initial success accelerated an AI culture that led to the deployment of ChatGPT Enterprise and its enhanced capabilities such as Advanced Analytics, Image Generation and GPTs. These GPTs are now embedded across Moderna's business functions - from legal, to research, to manufacturing, to commercial - and are purpose-built as assistants that work beside Moderna's employees, augmenting their roles through personalized support. With these tools serving as an extension to Moderna's team, the Company can advance its mission to deliver the greatest possible impact to people through mRNA medicines.
Lesen Sie auch
"Just as the introduction of the personal computer in the 1980's changed the way we work and live, AI is on a path to completely transform our everyday lives - and OpenAI is helping to lead the way. Both our companies have shared values and are research-driven organizations pushing the boundaries of technology to drive transformation," said Stéphane Bancel, Chief Executive Officer of Moderna. "Moderna has an ambitious plan to launch multiple products over the next few years, and collaborations with companies like OpenAI are critical to our ability to scale and maximize our impact on patients."